Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F09%3A33116051" target="_blank" >RIV/61989592:15110/09:33116051 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission

Popis výsledku v původním jazyce

Aims and Methods: The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation (ASCT) in 69 patients with poor-risk, diffuse large B-cell lymphoma (DLBCL). Results: A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x106/ kg in the non-R group and 7.81x106/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x104/kg) compared to the R group (76.6x104/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x104/kg) than the R patients (31.3x104/kg; p = 0.001). Conclusions: Hematopoietic engraftment wasrapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival

Název v anglickém jazyce

Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission

Popis výsledku anglicky

Aims and Methods: The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation (ASCT) in 69 patients with poor-risk, diffuse large B-cell lymphoma (DLBCL). Results: A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x106/ kg in the non-R group and 7.81x106/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x104/kg) compared to the R group (76.6x104/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x104/kg) than the R patients (31.3x104/kg; p = 0.001). Conclusions: Hematopoietic engraftment wasrapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers-Olomouc

ISSN

1213-8118

e-ISSN

—

Svazek periodika

153

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

4

Strana od-do

211-214

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—